Novartis AG (NVSEF) stock
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $279.46B
- P/E ratio
- 20.5
- Price to sales
- –
- Price to book
- 6.73
- Dividend yield
- –
- Free cash flow yield
- 6.30%
Fundamentals
- Net income
- $13.98B
- EPS, diluted
- $7.15
- Free cash flow
- $17.60B
- Book value per share
- $21.70
- Diluted shares
- 1.91B
Trading
- Previous close
- $143.90
- Open
- $153.25
- Day's range
- $146.46 – $153.36
- Volume
- 863
- Average volume (20 days)
- 53,310
- Beta (5 years)
- 0.42
- 52-week range
- $123.24 – $170.46
- RSI (14 days)
- 63.8
- Volatility (1 year)
- 27.3%
- Relative volume
- 1.24×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | NVSEF | S&P 500 | Difference | NVSEF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +9.5% | +0.6% | +8.9 pts | ||
| 3 months | -3.6% | +3.4% | −7.0 pts | ||
| Year to date | +6.1% | +13.3% | −7.2 pts | ||
| 1 year | +11.4% | +16.6% | −5.2 pts | ||
| 3 years | +68.4% | +86.4% | −18.0 pts | +19.0% | +23.1% |
| 5 years | +119.1% | +81.9% | +37.3 pts | +17.0% | +12.7% |
| 10 years | +184.6% | +318.9% | −134.2 pts | +11.0% | +15.4% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Novartis filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Novartis
Pharmaceutical Preparations
Novartis AG is an innovative medicines company focused on the research, development, manufacturing, distribution, and commercialization of prescription pharmaceutical products. Its operations are organized into five primary units: Biomedical Research, Development, Operations, and two geographic commercial divisions for the United States and International markets. The firm targets four principal therapeutic areas: cardiovascular, renal, and metabolic disorders; immunology; neuroscience; and oncology. Prominent marketed treatments include Entresto for heart failure, Cosentyx for systemic inflammatory conditions, Kisqali for breast cancer, Kesimpta for relapsing multiple sclerosis, and radioligand therapies like Pluvicto. Novartis supplies these medicinal products directly and through commercial operations to healthcare systems and patients worldwide.
Company profile, executives and historyNovartis stock: common questions
What is Novartis's stock price?
NVSEF closed at $146.46 on Oct 19, 2026, up 1.78% on the day. Over the past 52 weeks it traded between $123.24 and $170.46.
What is Novartis's market cap?
Novartis was worth $279.46B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is NVSEF's P/E ratio?
NVSEF trades at 20.5 times earnings, based on diluted earnings per share of $7.15 over fiscal 2025.
Does Novartis pay a dividend?
No. Novartis has not paid a cash dividend over the last twelve months.
How has NVSEF stock performed over the past year?
Including dividends, NVSEF returned +11.4% over the past year, against +16.6% for the S&P 500.
Who are Novartis's competitors?
Companies most similar to Novartis by business, industry and size include NVO, TEVA, OCS, NBP, REGN.
See a number that looks wrong?